SynthesisPharmacoEconomics2013
The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review.
Synthesis in PharmacoEconomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Costs of Invasive Meningococcal Disease: A Global Systematic Review.PharmacoEconomics · 2018Pooled it
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Article
- Article
- Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature.BMC public health · 2022Review
- Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM).Infectious diseases and therapy · 2022Article
- [Journal of preventive medicine and hygiene · 2021Article
- Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.PloS one · 2020Article
- Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.Frontiers in public health · 2020Article
- [Health Technology Assessment of meningococcal B vaccine (TrumenbaJournal of preventive medicine and hygiene · 2019Article
- A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.Health and quality of life outcomes · 2019Article
- Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.Human vaccines & immunotherapeutics · 2019Article
- Experience implementing a university-based mass immunization program in response to a meningococcal B outbreak.Human vaccines & immunotherapeutics · 2019Article
- Societal costs due to meningococcal disease: a national registry-based study.ClinicoEconomics and outcomes research : CEOR · 2018Article
- Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.Human vaccines & immunotherapeutics · 2016Article
- Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
- Public health management of invasive meningococcal disease in Baden-Wuerttemberg, Germany, 2012: adherence to guidance and estimation of resources required as determined in a survey of local health authorities.BMC public health · 2015Article
- Meningococcal serogroup Y emergence in Europe: high importance in some European regions in 2012.Human vaccines & immunotherapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundInvasive meningococcal disease (IMD) is a serious disease with a rapid onset, high mortality rate, and risk of long-term complications. Numerous reports in the literature conclude that IMD outbreaks are associated with substantial costs to society and significant burden on communities due to the cost associated with the prevention of secondary cases.
objectiveTo systematically review the literature on the costs and public health burden associated with IMD outbreaks.
methodsStudies were primarily identified through searching MEDLINE and EMBASE. Reports were included if they provided cost data related to the containment of an IMD outbreak after 1990 and were written in English, French, or Spanish. Costs were converted to 2010 United States dollars. Outbreaks were categorized by low-income countries (LIC) and high-income countries (HIC) based on gross domestic product per capita. Outbreak containment strategies were classified as small (e.g., targeting members of the school/institution where the outbreak occurred) or large (e.g., targeting everyone in the community).
resultsSixteen articles reporting data on 93 IMD outbreaks fulfilled the eligibility criteria and were included. The majority of outbreaks occurred in HIC. Five studies reported the use of small containment strategies including targeted vaccination and chemoprophylaxis, all occurring in HIC. The average cost per small containment strategy was $299,641 and the average cost per IMD case was $41,857. Eight studies reported large containment strategies involving widespread vaccination targeting a specific age group or community. For HIC, the average cost per large containment strategy was $579,851 and the average cost per IMD case was $55,755. In LIC, the average cost per large containment strategy was $3,407,590 and the average cost per IMD case was $2,222.
conclusionIMD outbreaks were associated with substantial costs. We found that although there were numerous reports on IMD outbreaks, data on containment costs were very limited. More research in this area is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.